Business
Neurocrine to Buy Soleno for $2.9 Billion
April 6, 2026
The Wall Street Journal - Business
Scroll
Neurocrine Biosciences agreed to buy Soleno Therapeutics for 2.9 billion in a move intended to expand its endocrinology and rare-disease portfolio.
The Wall Street Journal - Business
Coverage and analysis from United States of America. All insights are generated by our AI narrative analysis engine.
United States of America
Bias: lean right